Cantor Fitzgerald Downgrades Amgen(AMGN.US) to Hold Rating
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $329
Goldman Sachs Adjusts Price Target on Amgen to $400 From $408, Maintains Buy Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $350
UBS Maintains Amgen(AMGN.US) With Hold Rating, Cuts Target Price to $319
Amgen Is Maintained at Neutral by UBS
Amgen Analyst Ratings
Amgen (AMGN) Receives a Buy From Jefferies
Goldman Sachs Adjusts Price Target on Amgen to $400 From $408
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $329
Citi Maintains Amgen(AMGN.US) With Hold Rating, Cuts Target Price to $290
Morgan Stanley Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $330
Amgen Is Maintained at Equal-Weight by Morgan Stanley
Amgen Analyst Ratings
Morgan Stanley Keeps Their Hold Rating on Amgen (AMGN)
Goldman Sachs Adjusts Amgen Price Target to $408 From $370, Maintains Buy Rating
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $329
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $329
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $324
RBC Lifts Price Target on Amgen to $324 From $320, Keeps Outperform Rating